We evaluated the cost-effectiveness of a genotype-guided strategy among patients with acute coronary syndromes using a decision-tree model based on the Singapore healthcare payer's perspective over a 1-year time horizon. Three dual antiplatelet strategies were considered: universal clopidogrel, genotype-guided, and universal ticagrelor. The prevalence of loss-of-function alleles was assumed to be 61.7% and model inputs were identified from the literature. Our primary outcome of interest was incremental cost-effectiveness ratio (ICER) compared to universal clopidogrel. Both genotype-guided (72,158 SGD/QALY) and universal ticagrelor (82,269 SGD/QALY) were considered cost-effective based on a willingness-to-pay (WTP) threshold of SGD 88,991. In our secondary analysis, the ICER for universal ticagrelor was 114,998 SGD/QALY when genotype-guided was taken as a reference. Probabilistic sensitivity analysis revealed that genotype-guided was the most cost-effective strategy when the WTP threshold was between SGD 70,000 to 100,000. Until more data are available, our study suggests that funding for a once-off CYP2C19 testing merits a consideration over 1 year of universal ticagrelor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41397-020-00204-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Key Factors for Improving Predictive Accuracy and Avoiding Overparameterization of the PBPK Absorption Model in Food Effect Studies of Weakly Basic Water-Insoluble Compounds in Immediate Release Formulations.
Pharmaceutics
October 2024
Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.
Article Synopsis
- This study examines how physiologically based pharmacokinetic (PBPK) models can better predict drug absorption affected by food, specifically for weakly basic, water-insoluble drugs like rivaroxaban and ticagrelor.
- Researchers developed in vitro absorption models and combined them with disposition models to assess the drugs' systemic exposure in different dietary states, achieving moderate to high predictive accuracy, especially in Caucasian populations.
- The study emphasizes the significance of accurate permeability measurements to improve predictions and cautions against assuming precipitation behavior in vivo, advocating for evidence-based determination of rate constants to enhance PBPK model reliability.
Cost-effectiveness of platelet function testing in dual antiplatelet therapy decision-making after intracranial aneurysm treatment with flow diversion.
Neurosurg Rev
August 2024
Neurosurgical Service, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Dual antiplatelet therapy (DAPT) use is the standard of practice after flow diversion (FD) for intracranial aneurysms (IAs). Yet, no consensus exists in the literature regarding the optimal regimen. Certain institutions utilize various platelet function testing (PFT) to assess patient responsiveness to DAPT.
View Article and Find Full Text PDFBleeding is associated with severely impaired outcomes in surgery for acute type a aortic dissection.
Scand Cardiovasc J
December 2024
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
. Surgery for acute type A aortic dissection confers a risk for significant bleeding. We analyzed the impact of massive bleeding on complications after surgery for acute type A aortic dissection.
View Article and Find Full Text PDFThere is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are used to prevent ischemic outcomes in common diseases such as coronary and peripheral arterial disease and stroke. Clopidogrel, a prodrug, is the most used oral P2Y12 inhibitor and is activated primarily after being metabolized by a highly polymorphic hepatic cytochrome CYP2C219 enzyme. Loss-of-function genetic variants in are common, can result in decreased active metabolite levels and increased on-treatment platelet aggregation, and are associated with increased ischemic events on clopidogrel therapy.
View Article and Find Full Text PDFTicagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome.
JACC Cardiovasc Interv
June 2024
Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address:
Article Synopsis
- The study aimed to analyze whether ticagrelor is more effective than clopidogrel in reducing heart damage during elective coronary procedures for patients with and without prior clopidogrel treatment.
- Out of 1,882 participants, those who were not on clopidogrel had a lower rate of heart injury compared to those who had been, but overall, ticagrelor did not show significant benefits over clopidogrel for reducing complications.
- The findings suggest that clopidogrel-naive patients generally experienced fewer complications due to a lower risk profile and simpler procedures, with no notable differences in outcomes based on previously taking clopidogrel.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!